Acute graft-versus-host disease: New treatment strategies

Sophie Paczesny, Sung W. Choi, James L M Ferrara

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose of review: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. Recent findings: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. Summary Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.

Original languageEnglish (US)
Pages (from-to)427-436
Number of pages10
JournalCurrent Opinion in Hematology
Volume16
Issue number6
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Graft vs Host Disease
Cell Transplantation
Regulatory T-Lymphocytes
CD58 Antigens
Photopheresis
Therapeutics
Phase II Clinical Trials
Clinical Trials, Phase I
Natural Killer T-Cells
Sirolimus
Mesenchymal Stromal Cells
Dendritic Cells
Anti-Idiotypic Antibodies
Leukemia
B-Lymphocytes
Theoretical Models
Survival Rate
Tumor Necrosis Factor-alpha
Immunoglobulin G
Monoclonal Antibodies

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Graft-versus-host disease
  • Immunomodulatory drugs

ASJC Scopus subject areas

  • Hematology

Cite this

Acute graft-versus-host disease : New treatment strategies. / Paczesny, Sophie; Choi, Sung W.; Ferrara, James L M.

In: Current Opinion in Hematology, Vol. 16, No. 6, 11.2009, p. 427-436.

Research output: Contribution to journalArticle

Paczesny, Sophie ; Choi, Sung W. ; Ferrara, James L M. / Acute graft-versus-host disease : New treatment strategies. In: Current Opinion in Hematology. 2009 ; Vol. 16, No. 6. pp. 427-436.
@article{4754544197054ece9ace3cc15e1a6f3d,
title = "Acute graft-versus-host disease: New treatment strategies",
abstract = "Purpose of review: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. Recent findings: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. Summary Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.",
keywords = "Allogeneic hematopoietic cell transplantation, Graft-versus-host disease, Immunomodulatory drugs",
author = "Sophie Paczesny and Choi, {Sung W.} and Ferrara, {James L M}",
year = "2009",
month = "11",
doi = "10.1097/MOH.0b013e3283319a6f",
language = "English (US)",
volume = "16",
pages = "427--436",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Acute graft-versus-host disease

T2 - New treatment strategies

AU - Paczesny, Sophie

AU - Choi, Sung W.

AU - Ferrara, James L M

PY - 2009/11

Y1 - 2009/11

N2 - Purpose of review: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. Recent findings: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. Summary Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.

AB - Purpose of review: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), despite improvements in our understanding of its pathophysiology as well as the generation of new monoclonal antibodies, immunomodulatory chemotherapy, cellular therapeutics and supportive care. Herein, we review therapies that have proven effective as well as newer agents that have recently improved GVHD response rates and survival following HCT. Recent findings: Novel approaches to prevent or treat GVHD are often based on evidence from experimental models. Our understanding of the pathophysiology of GVHD may lead to the development of innovative strategies that target both soluble and cellular effectors. Among such agents are sirolimus, anti-tumor necrosis factor antibodies, anti-LFA-3-IgG fusion protein, extracorporeal photopheresis, mesenchymal stem cells and regulatory T cells. Summary Obstacles to the improvement of HCT include the tight linkage between GVHD toxicity and the beneficial graft-versus-leukemia (GVL) effect, as well as the impairment of immune reconstitution by immunomodulatory drugs leading to life-threatening infections. The design of newer phase I/II clinical trials are underway. Future therapies are likely to include modulation of cell types that play key roles in the GVH process, including regulatory T cells, dendritic cells, natural killer T cells and B cells.

KW - Allogeneic hematopoietic cell transplantation

KW - Graft-versus-host disease

KW - Immunomodulatory drugs

UR - http://www.scopus.com/inward/record.url?scp=73949155270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949155270&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e3283319a6f

DO - 10.1097/MOH.0b013e3283319a6f

M3 - Article

C2 - 19812490

AN - SCOPUS:73949155270

VL - 16

SP - 427

EP - 436

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 6

ER -